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ABSTRACT 
 
 The terrestrial organisms Streptomyces venezuelae and Rhaponticum repens produce 
toxic secondary metabolites that likely function as chemical deterrents.  The polyketide SV-6 
from S. venezuelae and the sesquiterpene lactone repin from R. repens both produce dose-
dependent and selective degeneration of dopaminergic neurons.  These molecules represent two 
possible tools that can be used to explore chemotoxic induction of Parkinson’s disease.  In the 
case of SV-6, a newly isolated metabolite, total synthesis was undertaken to confirm its structure 
and biological activity.  The natural product was produced from methacrolein and Roche ester 
starting materials that were elaborated to their respective fragments, a vinyl iodide and a 
Weinreb amide.  These fragments were coupled to form SV-6 and the synthesis allows for many 
additional opportunities to easily generate stereoisomers and analogs for further study.  In the 
case of repin, previously isolated material was used as a starting material to create a biotin-
labeled probe.  There were considerable challenges due to the electrophilic nature of the 
compound, but a Nicolas reaction followed by copper catalyzed cycloaddition produced an 
impure biotin-repin probe.  Repin was also subjected to screening in multiple biological assays 
which identified proteins potentially responsible for its neurodegenerative activity.  
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I. BACKGROUND INFORMATION 
 
Dopamine is the neurotransmitter most often regarded as a “reward molecule”, with its 
release punctuating food consumption and sexual intercourse, as well as the use of psychoactive 
drugs such as nicotine, amphetamines and cocaine
1
.  Interestingly, diseases that reduce dopamine 
production often effect movement and motor control as well as mood and behavior.  In 1817, 
James Parkinson described in “An Essay on the Shaking Palsy” the disease that now bears his 
name
2
.   The term “parkinsonism” is a blanket label of any condition consisting of bradykinesia 
or akinesia plus muscle rigidity, tremor, or unstable posture.  Increased emphasis has more 
recently been placed on non-motor components of this Parkinson’s disease (PD).  These aspects 
may include pain, fatigue, constipation, cognitive impairment and psychosis
3
.  The disease is 
progressive and may start with a slight tremor on one side of the body.  It can diminish facial 
expression, vocal tone and clarity of speech.  It may also cause stiffness or slowed movement 
4
.    
Approximately 1.5% of world’s population above the age of 65 is impacted  by the disease and 
the number of PD sufferers is expected to reach 8.7 million sufferers by 2030
5
.    
 
1.1 Parkinson’s Disease 
Parkinson’s disease is routinely broken into two groups, sporadic and familial cases.  The 
disorder was once considered to be entirely sporadic- meaning it has no genetic basis
6
.  
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However, there have been great advances in understanding the genetic origins of the diseases. It 
is now thought that roughly 10% of patients have monogenic (familial) forms of PD
6
.  The 
disease is a complex manifestation of various environmental factors in combination with some 
specific genetic susceptibilities.  Among the genes consistently implicated in PD development 
are SNCA, LRRK2, GBA, PRKN, PINK1, PARK7, VPS35, EIF4G1, DNAJC13 and CHCHD2.  
Some of these genes (SNCA, LRRK2, GBA) are considered key in development of both familial 
and sporadic forms
7
. The discovery of these genes and their products has led to the development 
of some useful genetic animal models of the disease
8,9
.  While these models are helpful, the exact 
role of genetic factors with the environment is lacking and therefore remains a great need for 
chemotoxic models.  
 
1.2 Mitochondria, Metabolism and Neurodegeneration 
Mitochondria are cellular organelles which produce energy via a series of coupled 
biochemical processes.   Through ATP and the electron transport chain, they generate the largest 
proportion of cellular energy and are common to nearly all eukaryotic cells. Mitochondria form 
reticular networks in cells and density of this network varies between cell and tissue type relative 
to oxidative phosphorylation-dependent energy demands.  Among those with the highest 
requirements are cardiac and skeletal muscles as well as neurons
10
.  Due to a heritage predating 
eukaryotic incorporation, mitochondria bear DNA which is distinct from that of their host cells. 
Human mitochondrial DNA (mtDNA) is roughly 16.6 kilobase pairs in length. This material 
consists almost entirely of exons and encodes two ribosomal RNA units, 22 transfer RNA units, 
and 13 proteins.  The dependence of these organelles upon the eukaryotic home it resides in for 
replication, repair, transcription and translation is probably at the root of many disease states.  Of 
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the aforementioned 13 mtDNA encoded proteins, all are subunits of oxidative phosphorylation 
system and respiratory chain (OXPHOS).  The inner mitochondrial membrane contains the five 
OXPHOS complexes. There are about 85 protein subunits across all OXPHOS complexes and all 
complexes are required for sustenance of energetic requirements
11
.  
 
Figure 1: Interplay between genetic and environmental factors in PD  
 
In addition to mutations in mtDNA, the release of and exposure to reactive oxygen species 
(ROS) are considered significant drivers of the aging process (Figure 1).  There are a number of 
factors for which the brain—and its dopaminergic neurons—are disproportionately affected by 
these insults.  The brain is rich in easily oxidized fatty acids and it also has a high rate of oxygen 
consumption. This intense ROS generation coupled with a lower amount of antioxidant enzymes 
relative to other tissues sets the stage for numerous cellular damage scenarios to unfold.  
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Dopaminergic neurons are especially susceptible to ROS damage via metabolic products of 
dopamine 1.1
12,13
.  
Medical researchers now believe that this fundamental energy metabolism may have far-
reaching implications in disease and cellular dysfunction
14
.  Nuclear or mitochondrial gene 
mutations can have direct consequences on mitochondrial health.  The overlap of genomic 
susceptibility and environmental exposure may account for the incidence and variety of diseases 
of mitochondrial origin that seems to be unexplained when looking at each factor individually. 
Environmental exposure to cyanide and rotenone are known to inhibit mitochondrial components 
complex IV and complex I 
15,15b
.  For example, a group of 50,000 people suffering from folate 
deficiency responded to cyanide or methanol exposure with symptoms of optical neuropathy that 
were similar to Leber’s Hereditary Optical Neuropathy16.  Leber’s is a mitochondrial disease of 
genetic predisposition.  Other diseases of mitochondrial origin include Leigh Syndrome, 
Diabetes Mellitus and potentially many others. Parkinson’s Disease, while typically associated 
with degeneration of dopaminergic neurons is thought to have some mitochondrial origin
17,18
.    
 
1.3 Molecular Factors in Biology of Parkinson’s and Related Diseases 
There are some well-known players in this denerative pathway such as α-synuclein, 
Parkin and PINK1. α-Synuclein is a neuronal protein thought to contribute to Parkinson’s 
through formation of soluble oligomeric aggregates known as protofibrils. While presynaptic in 
origin, α-synuclein can be secreted, leading to disease propagation by seeding further 
aggregation in neighboring cells.
19
  While the extent of α-synuclein’s role in Parkinson’s is not 
entirely clear, it is thought to participate in other neurodegerative conditions collectively labeled 
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synucleinopathies.  α-Synuclein which is naturally unfolded, can be phosphorylated at Ser129, 
which plays some role in aggregation into Lewy bodies.  Parkin, a cytosolic ubiquitin ligase, was 
once implicated in this phosphorylation at Ser129, although it now thought to de-phosphorylate 
at both Ser87 and Ser129, which reduces cellular damage and death in synucleopatheies
20
. 
PINK1 (PTEN-induced putative kinase 1) aggregation occurs on the outer membrane of 
damaged mitochondria and acts as a signal for their destruction. It is believed that PINK1 and 
Parkin work cooperatively. PINK1 activates and recruits Parkin from the cytosol, which in turn 
phosphorylates and ubiquitinates the outer membrane, initiating selective autophagy.
21
 In this 
model, both excessive damage to these organelles by toxins (MPTP, paraquat, rotenone and 
others), and the inability to clear dysfunctional mitochondria may both lead to neuronal cell 
death and Parkinson’s disease.      
 
1.4 Environmental Toxins and PD: 6-OHDA and MPTP 
The two most explored toxin models for PD are 6-hydroxydopamine (6-OHDA) and 1-
methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) 1.2 (Figure 2).  They are the oldest models 
and also share some common mechanistic traits and limitations.  6-OHDA was introduced in the 
late 1900s making it the first PD toxin model to be developed
14
.  When 6-OHDA is administered 
systemically, it causes destruction of sympathetic nerve terminals in the peripheral nervous 
system
22
.  Due to the chemical similarity of both 6-OHDA and the active metabolite of MPTP to 
endogenous neurotransmitters, they actively cross the blood-brain barrier (BBB) via 
catecholamine transporters
23,24
.  A possible explanation for the regioselectivity of these toxins is 
that midbrain neurons have the highest concentration of dopamine transporter (DAT) per cell
25
.  
DAT presence is required for MPTP-induced toxicity, as evidenced by mice mutants with DAT 
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deletions
26
.  To enhance the selectivity of 6-OHDA, it is sometimes co-administered with 
desipramine 1.3, a selective noradrenaline reuptake inhibitor
27
. 
 
Figure 2 
 
1.5 Metabolism and Activation of 6-OHDA 
The location of 6-OHDA injection into the brain directly relates to its neurodegenerative 
effect.  If injected into the midforebrain (MFB), non-apoptotic morphology is exhibited within 
24 hours whereas protracted retrograde degeneration can take place for a window of up to three 
weeks if injected into the striatum
28
.  Striatal injection produces morphology akin to apoptic 
degeneration.  For this reason 6-OHDA models must be differentiated by injection site.  MFB 
injections lead to rapid degeneration within a few days followed by a gradual decline to near 
complete lesion in five weeks
29
.  Striatal injection causes more gradual damage in a dose-
dependent pattern.  For this reason, it is preferred when modeling initial stages of PD
30
. 
Toxicity initiates as the dopamine transporter releases 6-OHDA into the cell followed by 
non-enzymatic auto-oxidation
31
.  This oxidation leads to formation of superoxides, quinones and 
other radical species and causes downstream damage.  This oxidative stress hypothesis is 
bolstered by the fact that overexpression of glutathione peroxidase and superoxide dismutase 
protect mice from 6-OHDA-induced damage
32,33
. In vitro analysis of the pathways of MFB and 
striatally-induced 6-OHDA degeneration has been performed.  MFB injection more closely 
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resembles necrotic cell death than striatal administration and can be rescued by use of a general 
caspase inhibitor
33
.  Inihibition of the c-jun-N-terminal kinase (JNK) in rats and JNK deletions in 
mice have both demonstrated protective effects in MFB and striatal 6-OHDA studies, 
highlighting a common pathway in both models
34,35
.  
 
1.6 MPTP Discovery, Metabolism and Activation 
MPTP 1.2 was discovered serendipitously at the interface of clandestine drug synthesis 
and forensic chemistry.  A chemistry graduate student was seeking to synthesize meperidine 
analog (1-methyl-4-phenyl-4-propionpiperidine) 1.5 for personal use.  Despite early successes, 
he allowed the reaction temperatures elevate, generating an ester that, following metabolism, 
forms an alcohol that is subject to elimination reaction and accidentally created MPTP (see 
Figure 3)
36
.   
 
 
Figure 3: Synthesis of desmethylprodine and MPTP (MP= 1-methylpiperidin-4-one, HPMP= 1-methyl-4-
phenylpiperidin-4-ol)  
 
Following self-administration of this batch, he rapidly developed bradykinesia that was 
alleviated with L-dopa 1.4.  Subsequent forensic analysis of his labware determined these details.  
Initial injection studies in mice failed to produce such dramatic symptoms.  However, later 
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rediscovery of MPTP across the country several years later by a similar synthetic mistake lead to 
injection of the material into monkeys.  This chapter confirmed the acute toxicity of MPTP in 
humans while underlining important neurochemical differences between rodents and primates. 
MPTP was confirmed as a chemical probe capable of producing all of the PD hallmarks of 
rigidity, tremor and instability among others
37
.     
Although MPTP was overlooked in rodents initially, much effort has gone into 
developing this model.  As it turns out, rats have are uniquely resistant to the effects of MPTP 
whereas mice are more susceptible.  However, certain susceptibilities within mouse 
subpopulations (strain, age, gender) must be taken into account when selecting a model.  
Due to the popularity of the MPTP model, much has been elucidated of the pathways by 
which it causes neuronal cell death.  MPTP acts indirectly as a protoxin that eventually forms the 
metabolite 1-methyl-4-phenylpyridinium 1.5, or MPP+ 
38
.  Following systemic administration in 
primates, the lipophilic character of MPTP allows rapid crossing of the blood-brain barrier.  
Monoamine oxidase B (MAO-B) performs oxidation to 1-methl-4-phenyl-2,3,-
dihydropyridinium (MPDP+) is thought to take place in the glial or serotonergic cells
39
.  From 
here, MPDP+ undergoes further oxidation to MPP+, and gains access to dopaminergic neurons 
via the dopamine transporter (DAT) for which it has high affinity.  This role of DAT is supported 
by genetic deletion and inhibition of DAT by small molecules- both measures prevent MPTP 
neurotoxicty in vivo
40,41
.  Also of note is that DAT concentrations are highest in the midbrain 
cells which may explain the unique sensitivity of these cells toward MPTP-induced damage
26
.   
As MPP+ enters neurons, it begins to accumulate in the synaptic vesicles and in the 
mitochondrial matrix by passive transport.  MPP+ then collects in the mitochondria, it binds to 
complex I of the electron transport chain.  This step of the chain allows for oxidation of NADH 
9 
 
substrates and inhibits further electron shuttling steps from taking place.  This also leads to a 
decrease in ATP production and increased ROS production.  Meanwhile, there is an 
accompanying spike in vesicular dopamine release induced by MPP+.  This dopamine is subject 
to auto-oxidation that acts as another source of damaging ROS
42
.   
Both 6-OHDA and MPTP have been explored thoroughly in animal research models.  
There are specific, important differences such as animal selected, and which brain region is the 
target of degeneration.  Despite their limitations, they represent the best explored tools available 
and these limitations highlight the importance of increasing the chemotoxic toolkit for PD 
research.  
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II. DISCOVERY AND SYNTHESIS OF BACTERIAL METABOLITE SV-6 
 
2.1 Discovery of a Novel Neurotoxic Metabolite from S. venezuelae 
 A metabolite isolated from Streptomyces venezuelae caused age-related and dose-related 
degeneration of all Caenorhabditis elegans neurons, with dopaminergic neurons specifically 
degenerating more rapidly.  Human neuroblastoma cells were also exposed to the metabolite.  In 
this assay, the SH-SY5Y-derived cells in culture showed degeneration in a dose-dependent 
fashion following exposure
43
.  Initial investigations of the metabolite suggest that it causes cell 
death through decreased ATP production, increased reactive oxygen species (ROS) and 
modulation of mitochondrial complex I
14,44
. The metabolite also disrupts protein homeostasis, 
ubiquitin proteasome activity and glutathione response to α-synuclein toxicity by loss-of-
function of pink1 
44
.  These molecular changes were seen in all cells of C. elegans, but due to the 
high energy demands of muscle and neuronal cells, these changes were more obvious 
43,14,44
. 
Our collaborators at the University of Alabama (Department of Biology; Tuscaloosa, AL) 
have worked for some time on modeling PD in a genetically invariant hermaphroditic C.elegans 
(Nematode) model.  The worm has considerable evolutionary distance from humans, but bears 
many important features that make it a useful for understanding PD neuropathology and also a 
testing ground for potential therapies
45
.  Beginning with work performed by Sydney Brenner in 
the 1970s to understand neuromuscular development, it has since revolutionized our 
11 
 
understanding of genomics, epigenetics, cell biology and aging
46
.  The worm has only 952 total 
cells, and almost a third of which are neurons, and represents the most thoroughly mapped 
neuronal circuitry and cell lineage of any model species
47
.  Its 302 neurons retain many 
important features of its mammalian counterpart such as receptors, ion channels, 
neurotransmitters, vesicular transporters and other synaptic components.  It is rapidly cultured 
and transparent, which allows for degenerative assessment of six anterior dopaminergic neurons 
using an indicator such as green fluorescent protein (GFP)
48
.  C.elegans has been exploited for 
PD research with dopaminergic circuitry consisting of a mere eight anatomically defined 
neurons.  The organism’s genetic loci for PD risk factors are similarly defined and are termed 
“PARK”, with 21 sites currently identified.  Of these, only six are connected to 
familial/monogenic PD.  These are SNCA (α-synuclein), VPS35, LRRK2, PINK1, PRKN 
(Parkin), and DJ-1
49
.  C. elegans expresses all of these homologs except α-synuclein, which is a 
considerable exception. However, a variety of α-synuclein overexpression experiments have 
accurately modeled the progressive degenerative and motor deficits expected in PD
50
.  
Additionally, α-synuclein misfolding can be traced by use of green-fluorescent fusion proteins 
which express into the bodywall muscle cells
51
. 
Our collaborators’ work is not the only evidence that microbial communities may 
contribute to PD.  A study by Sampson et al. reported the effect of “gut microbiota on regulation 
of motor deficits and neuroinflammation” in a mouse PD model52.  This study demonstrated a 
number of interesting patterns connecting gut microbes to PD.  In mice overexpressing α-
synuclein, gut microbes are required to produce microglial activation and synuclein pathology.  
Treatment with antibiotics ameliorated these effects, while microbial recolonization promoted 
pathophysiological symptoms.  Oral administration of microbial metabolites also promoted 
12 
 
neuroinflammation and motor disturbances.  Finally, the mice overexpressing α-synuclein were 
colonized with microbiota from either healthy or PD-affected human donors. Those mice 
exposed to the microbiota from PD-affected humans displayed deterioration in motor function in 
agreement with PD symptoms.             
 
2.2 Innovation Toward a Better Chemotoxic Toolkit 
Our understanding and treatment of Parkinson’s Disease (and other neurodegenerative 
diseases of mitochondrial origin) has been limited by the existing animal models used to study 
the disease.  These animal models often require exposure to toxins such as MPTP and rotenone.  
These compounds are useful, but still leave a gap in our understanding.  Increasing research into 
the chemical induction of PD-like symptoms is a much needed innovation not just Parkinson’s 
but for other mitochondrial diseases of neurodegeneration.  Natural products provide an 
interesting subset of these chemicals as they may have been preserved in the environment over 
evolutionary time as a protection mechanism.   It is speculated that only 5-15% of the 
Parkinson’s population stems from hereditary factors, leading researchers to look into 
environmental factors (toxins, microbiota) as important contributors to disease development
9
.   
Figure 4 shows some natural products with mitochondrial toxicity are rotenone, iromycin, repin 
and the recently identified molecule SV-6 2.8 
15a, 53
.    
 
13 
 
 
Figure 4. Mitochondrial toxins 
14 
 
2.3 Discovery and Significance of SV-6 
The target molecule SV-6 2.8 was isolated from a bioassay-guided fractionation and 
purification.  Spent S.venezuelae growth media was extracted, yielding 300 mg of crude material 
that was subjected to reverse-phase liquid chromatography (RP-HPLC).  To test these fractions, 
they were exposed to C. elegans in an established neurodegeneration assay
45
.  Further 
purification of this active fraction lead to isolation of one milligram of material that displayed 
significant activity.  This material was subjected to high-resolution electrospray ionization mass 
spectrometry and nuclear magnetic resonance to generate the putative structure.   
In a related study performed by our collaborators, field collections of various 
Streptomyces species not limited to S. venezuelae were performed across the state of Alabama 
with the goal of determining how prevalent this toxin might be (Figure 4).  Samples were 
collected and organized by three categories of land-use type and physiography. The first was 
agricultural soils (AG) used for crops and livestock grazing.  The second was soils from 
undeveloped (UD) soils with multiple tree species and dense undergrowth.  The last category 
was developed or urban (UR) soils near human populations but excluding lawns and landscaped 
soils
54
.    All three soil types were collected from across the major physiographic provinces of 
Alabama to represent the topographic and geologic diversity of the state (Figure 4).   
15 
 
 
Figure 5 Colors represent the physiographic provinces and data points (•) indicate sampling locations. 
(Map courtesy of the University of Alabama Cartography Lab) 
54
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The study showed that Streptomyces isolates by soil type varied with “a significant difference 
found in the number of isolates obtained between agricultural and undeveloped soils” while there 
was no difference between isolates when compared across physiographic provinces (Figures 5 
and 6). 
 
Figure 6 “(A) Exposure to environmental isolates of Streptomyces spp. can cause significant 
neurodegeneration in populations of C. elegans. (B)  Streptomyces spp. isolated from agricultural soils 
caused significantly more dopaminergic neurodegeneration.”54 
 
Isolates of Streptomyces from each land use were selected and cultured where possible- 
approximately half the Streptomyces species isolated did not grow in the SYZ media that was 
selected to aid in production of secondary metabolites.  Of those that did grow successfully, 
supernatants were collected and assessed in the neurodegeneration C. elegans model system.  
From this group, 28.3% the Streptomyces spp. isolates (51 of 180 strains) produced 
dopaminergic neurodegeneration in C.elegans versus 0.4% in the control group used in this study 
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(E.coli extracts).  When activity was tracked back to land use type there were more isolates from 
agricultural and undeveloped soils with neurodegenerative activity compared to urban soils 
(Figure 7).  
Figure 7  “(A) Comparison of the average number of isolates obtained from dilutions of 0.25 g of 
agricultural (AG), undeveloped (UD) and urban (UR) soils. (B) n = 60 for each land use. Columns with 
the same letters are not significantly different from one another (Fisher’s exact test, p < 0.01).”54 
 
 This led the authors to conclude that there was a neurodegenerative compound(s) being 
produced in the soil responsible for the Parkinsonian-like symptoms seen in rural populations 
that were not previously accounted for by other environmental factors such as herbicide, 
fungicide and pesticide exposure
54
.  Furthermore, the authors hypothesize that there is a common 
mitochondrial toxicant across many of these Streptomyces isolates.  The authors believe that SV-
6 may be a common toxicant and total synthesis help in understanding its ecological distribution 
and mechanism of action.   
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2.4 Structure of SV-6 
 SV-6 2.8 is a 13-membered linear polyketide that bears structural similarities to other 
metabolites from S. venezuelae.  Figure 8 below highlights the structural similarity of SV-6 with 
methynolide 2.10 and pikromycin 2.11.  Of note is the 10-hydroxy group that is shared across all 
the structures and may be a product of PikC oxidation instead of polyketide synthase 
metabolism
55
.  Pik pentakide 2.13 is a common biosynthetic precursor to both methynolide and 
pikromycin
56
.  It is important to note that the stereochemistry of SV-6 in this figure is only 
hypothetical and based on the known metabolites from S.venezuelae.  Only following the total 
synthesis of SV-6 and comparison to the isolated metabolite can this structure be confirmed.   
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Figure 8 
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2.5 Polyketide Synthase and the Biosynthetic Origin of SV-6 
While a vast diversity of structures are enabled by strict implementation of polyketide 
synthase machinery, there are even more possible variations enabled by incorporation of 
alternate starter or extender units (Figure 9). 
 
Figure 9  General biosynthetic format of polyketide pathway responsible for aromatics, macrolides and 
fatty acids
57
. 
   
In addition to malonyl and acetyl-CoA units, Figure 10 shows the PKS can also use propionyl-
CoA units which can be converted into methylmalonyl-CoA extender units by addition of CO2 
by propionyl-CoA carboxylase. This allows for methyl groups to be installed between carbonyl-
bearing units.  Some bacteria can also incorporate iso-fatty acids in the PKS pathway.  These 
branched chain fatty acids are otherwise used to maintain membrane fluidity.   They are 
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generated from branched chain amino acids and serve as alternate PKS starter units. Leucine, 
isoleucine and valine lead to isovaleryl-CoA, 2-methybutyryl-CoA and isobutyryl-CoA 
respectively (Figure 10).  
 
Figure 10 Incorporation of branched motifs into PKS pathway products
57
. 
  
In the case of SV-6 it seems probable that isobutyryl-CoA was used as a starter unit followed by 
incorporation of multiple methylmalonyl-CoA units.  In addition to the variety of loading and 
extender units and subsequent reductions and dehydration steps, there is potential for other 
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tailoring steps following PKS release, such as decarboxylation, Pik oxidation and to form 
macrocyclic lactone rings.  In the case of SV-6, there is a disparity in carbon count and acetate 
incorporation pattern.  It is possible that the parent unit was decarboxylated then subjected to 
redox transformations to result in the proposed structure for the isolated natural product (see 
Figure 11). 
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Figure 11 General biosynthetic hypothesis for PKS assembly of SV-6. Main assembly (top), followed by 
post-PKS release tailoring steps (bottom).   
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2.6 Initial SV-6 Synthesis Plan: Andrade and Breit Fragments 
To date, neither the structure nor the synthesis of the target molecule SV-6 has been 
published.   Although the synthesis will be new, the plan is to rely on well-established methods 
for producing polyketides.  The final compound could be produced in a convergent fashion by 
coupling two fragments such as a vinyl iodide and aldehyde (Scheme 1) fragment A 2.13 and 
fragment B 2.14, followed by oxidation and deprotection (Fig.2).  Our confidence in this 
approach was based on the successful syntheses of similar polyketides tridesmethyl 
telithromycin, and vittatalactone by the groups of Andrade and Breit, respectively
58,59,60
.  
Scheme 1 Disconnection between fragments A and B 
 
Scheme 2 Initially planned fragment A synthesis 
 
Fragments A and B may be derived from enantioselective alkylations of simple α,β-
unsaturated aldehyde starting materials methacrolein 2.15 and crotonaldehyde 2.22 with 
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diethylzinc.  In the case of fragment A, the alcohol 2.16 could be oxidized to the epoxide 2.17 
using Sharpless asymmetric epoxidation
61
.  This is followed by ring opening with pivalic acid to 
selectively protect the least hindered position
59
.  At this point, the 1,2 diol 2.18 can be protected 
with an acetal 2.19.  The pivalate group can be removed using methyllithium, and then oxidized 
to the aldehyde 2.21.  Takai-Utimoto olefination will be used to finish fragment A 2.13. 
Scheme 3 Initially planned fragment B synthesis 
 
The synthesis of Fragment B 2.14 continues from a distinct allylic alcohol than fragment 
A.  First, a Steglich esterification with ortho-diphenylphosphanylbenzoic acid (o-DPPBA) 2.24 
is performed, and a portion of this product 2.25 is retained for a later step (Scheme 3, step g).  
Stereospecific addition of the branched bromide to the ester in a copper-assisted Grignard 
reaction (Figure 12) followed by ozonolysis concludes the synthesis of fragment B.  This 
iterative approach using o-DPPB esters has proven effective in longer polyketides by Breit and 
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co-workers
60
.  Cleavage of the double bond with ozonolysis (or alternative method), followed by 
reduction and Appel reaction leads us to an intermediate 2.26 to be reacted with previously 
generated o-DPPB ester 2.25
62
. 
 
Figure 12 Breit's proposed mechanism of stereoselectivity 
 
Fragment A and fragment B would be connected via a Nozaki-Hiyama-Kishi reaction (Scheme 
4).  This reaction has previously been proven effective in the synthesis of other polyketides such 
as telithromycin, palytoxin, and halichondrin B
59,63,64
. 
Scheme 4 
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2.7 Enantioselective Oganozinc Alkylations of Aldehyde Building Blocks 
It was envisioned that both starting materials could be derived from enantioselective 
alkylations of simple enone starting materials methacrolein 2.15 and crotonaldehyde 2.22 with 
diethylzinc (Scheme 5).  This enantioselective counterpart to the Grignard addition reaction is 
based on the pioneering work of Noyori, which established the utility of β-amino alcohols such 
as DAIB 2.32  (Scheme 6) to enantioselectively control addition of diorganozincs to aldehydes
65
.   
Scheme 5 
 
Diaorganozincs were held to be an ideal alkyl donor due to their sp-hybridized linear 
geometry. The alkyl-metal bond was relatively nonpolar, but it could be bent to induce reactivity 
toward carbonyls upon perturbation by external ligands.  The formation of stable alkylzinc 
alkoxide tetramers in hydrocarbon solvents following release of anionic ligands could also be 
leveraged as a driving force for the reaction (Scheme 6).  Addition of diethylzinc addition to 
aromatic aldehyde substrates fared best in yield, enantiomeric excess and reaction time.  Alkyl 
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aldehydes and longer alkyl groups in the organozinc agents both performed poorly.  α,β-
unsaturated aldehydes performed somewhere in the middle.  Methacrolein and crotonaldehyde 
were both explored in this initial report, but not optimized.  
Scheme 6 
 
Later, Nugent and coworkers at Bristol-Myers Squibb performed parallel synthesis 
techniques to more thoroughly understand the structure-activity relationships of β -amino alcohol 
ligands in asymmetric organozinc alkylations
66
.  They too focused on benzaldehyde 2.32 as their 
test substrate.  In a follow-up study it was determined that a tertiary amine substructure bearing 
piperidinyl or morpholinyl rings was optimal in all cases
67
.  N-terminal and O-terminal 
substituents were both deemed critical and simplified amino alcohols performed abysmally.  
Introduction of a phenyl group to N-teminal position dramatically improved enantioselectivity to 
83% while introduction of a cyclohexyl group increased enantioselectivity to 67%. The 
combination of both features proved yielded a new ligand 2.30 that could be produced in two 
steps.  In this case, catalyst loading of 5% both aromatic and α,β-unsaturated aldehydes 
(including methacrolein) performed well while alkyl aldehydes still performed poorly.   
In a recent update to this method by Myers and co-workers, the conditions for this 
reaction were optimized.  In this case, they needed to produce large quantities of (R)-2-
methylpent-1-en-3-ol 2.16  from methacrolein 2.15
68,69
.  In their work, they were able to modify 
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addition protocol which resulted in both a reduction in catalyst loading and a reduction in 
transfers of pyrophoric diethylzinc.  They found that by adding diethylzinc to a suspension of 
catalyst followed by slow addition of methacrolein followed by aqueous-acidic workup they 
could also recover their ligand in high purity.  They also changed the solvent from hexanes-
toluene (2:1) to pure hexanes.  Using catalyst loading of 1% and reaction temperature of 0
o
C, 
they attained product in 76% yield with 99% ee.  With these studies from Noyori, Nugent and 
Myers as a guide, we would attempt to extend this method to crotonaldehyde as a substrate using 
a tert-butyl morpholine ligand to produce an analogous ethylation product, hex-4-en-3-ol 2.23.  
Scheme 7 
 
In regard to SV-6, the work began by synthesizing the ligands to be used (Scheme 7).  
Next, these were to be applied to the synthesis of fragment B because the starting material, 
crotonaldehyde was much less expensive than methacrolein ($0.20 versus $6 per milliliter).  This 
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would allow me to test the ligand-directed diethylzinc reaction on a more affordable starting 
material.  Both ligand 2.30 and 2.31 were made in two steps.  This was followed by asymmetric 
ligand-directed alkylation of crotonaldehyde with diethyl zinc and 2.31 based on the work of 
Noyori and Myers
70,68
.  At small scale this reaction seemed to have some impurities.  It was 
initially performed on a scale too small too effectively perform vacuum distillation on.  Initial 
attempts at purification with column chromatography were challenging due to the small size and 
nonpolar nature of the compound.  Spectra indicated some impurities but there was uncertainty 
as to if they were oxidation products (unlikely), solvent impurities or residual chromatography 
solvents.  Only after scaling the reaction up was it apparent that the reaction had produced a 
mixture of products (Scheme 8), with our intended product being the major component.  
However, this mixture was not separable further by column chromatography or distillation.  
After realizing this fact, the ligand-directed alkylation was abandoned.  
Scheme 8 
 
 
2.8 Overhauled SV-6 Synthesis Route  
Due possibility for rearrangements and associated loss of optical purity, a new route was 
adopted with some advantages.  It would also be safer- no longer requiring large-scale 
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diethylzinc and ozonolysis reactions.  Existing procedures for many intermediates were 
detailed
58,56
.  This route would also simplify access to isomers and analogs of SV-6 (Figure 13).  
The commercially available Roche ester starting materials contains a stereogenic center that will 
appear in the final product.  The only downsides were is that this route did not have as many 
opportunities to explore reaction development and the Roche ester starting material is more 
expensive.    
 
Figure 13: Modular access to various stereoisomers and analogs 
 
2.9 Fragment A Synthesis: Cossy Fragment 
Following the mixed results of the zinc alkylation, it was decided to use a route that was 
based on the best documented chemistry possible (Scheme 9).  There was a related route taken 
by Cossy et al. that also ended with haloolefination to yield the final product
58
. It began with a 
reaction of methacrolein with an ethyl Grignard reagent.  This formed the racemic mixture of 
(E)-hex-4-en-3-ol enantiomers.  These were effectively resolved using Sharpless conditions
61,71
.  
Silyl protection of the allylic alcohol followed by dihydroxylation formed a mixture of 
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diastereomers that were chromatographically inseparable.  These were carried forward though 
oxidation to the aldehyde, haloolefination and deprotection.  Following deprotection of the silyl 
ether, the mixture became easily separable on silica gel.  Treatment of the diol with 
dimethoxypropane and pyridinium p-toluenesulfonate yielded the protected vinyl iodide that 
would be used to couple with fragment B.   
 
Scheme 9 
 
 
2.10 Fragment B Synthesis:  Roche Ester and Pseudoephedrine Chiral Auxiliary  
 Synthesis of pseudoephedrine propionamide 2.53 and TBS-protected iodide 2.57 
proceeded smoothly before encountering problems (Scheme 10).  First, the chiral Roche ester 
was purchased from Sigma-Aldrich, protected with a tert-butyldimethylsilyl protecting group.  
The protected ester was reduced with DIBAL to the alcohol which was displaced to the iodide 
under Appel conditions.   
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Scheme 10 
 
By far the most troublesome reaction of the entire SV-6 synthesis was the alkylation of 
(R,R)-pseudoephedrine propionamide 2.53 with the TBS-protected iodide 2.57.  The related 
reactions were reported in the literature with yields up to 95% so this difficulty was 
unforeseen
72,73,56
. Moisture sensitivity was expected for this reaction but even with careful 
application of anhydrous techniques the yield plateaued at 15%.  The purified product matched 
data published for the compound but attempts to increase yield were met with failure.  Different 
batches pre-prepared LDA and LiHMDS were used to no success.  Diisopropylamine was 
repeatedly distilled over activated molecular sieves and n-butyllithium sources where repeatedly 
titrated.   The reaction duration and temperatures were varied as were equivalents of reagents 
used in the reactions.  Both pseudoephedrine propionamide 2.53 and protected iodide 2.57 
starting materials were resynthesized numerous times to no avail.  Test reactions using benzyl 
bromide instead of the protected iodide 2.57 were also performed to narrow down the cause of 
the problem.   
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Scheme 11 
 
This well-supported transformation presented a surprising challenge, and was temporarily placed 
on hiatus while I synthesized fragment A.  After returning to this reaction, it was rerun with a 
previously opened bottle of LDA which surprisingly yielded 80%.  The reaction was 
immediately repeated at larger scale using the same batches of every reagent, resulting in a yield 
of 75% (Scheme 11).  Although this reaction worked well enough to move forward, there was 
never a scientifically satisfying conclusion as to why it did not work initially.     
The first plan was to use alkyllithium reagents to displace the chiral auxiliary and then 
reduce the carbonyl.  This exact reaction is unreported, but its closest analogs use t-butyllithium, 
phenyllithium and n-butyllithium, with maximum reported yields of 71%, 98% and 95% 
respectively 
74,75,76
.  At this point, the Clemmensen approach was reappraised with an eye to 
possible issues such as epimerization (Scheme 12). 
Scheme 12 
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  Other routes were all considered and the step-count and reaction yields from similar 
systems in the literature were all compared before finding a suitable replacement.   In the 
selected approach (Scheme 13), I opted to first reduce the amide auxiliary to the primary alcohol 
2.61. It could then be transformed to a tosylate 2.62, which would be displaced with a copper-
assisted alkyllithium.  The ammonia-borane reduction worked well but the tosylation had yields 
of 30-40%.  The solvent was changed from dichloromethane to pyridine, improving conversion 
to 99%.  The resulting product 2.60 was deprotected with tetrabutylammonium fluoride and 
oxidized with nickel (II) chloride and commercial bleach (sodium hypochlorite)
77
.   
Scheme 13 
 
Unfortunately, the yield for the nickel (II) chloride oxidation was less than 15%.  It was a very 
complex TLC and the main polar product was isolated and matched expected molecular weight 
when analyzed with ESI mass spectrometry.  It was not characterized further.  Instead of 
optimizing a reaction with limited literature support, the reaction was abandoned
77
.  I attempted 
an alternative oxidation using TEMPO, sodium hypochlorite and sodium chlorite
78
.  This 
reaction went smoothly and after achieving a yield of 77% (Scheme 14), the reaction scale was 
increased and the resulting material was taken forward to the next step. 
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Scheme 14 
 
 Water soluble carbodiimide (EDC) in DMF with standard amide coupling conditions was used 
to form the Weinreb amide product 2.65 (Scheme 15).  The reaction yielded 45% but without 
any more acid starting material, this was all that would be used for the remaining steps of the 
synthesis.   
Scheme 15 
 
The second to last step was a coupling reaction between the fragments 2.13 and 2.14 
(Scheme 16).  A vinyl lithium species from vinyl iodide 2.13 and t-butyllithium is prepared in 
situ to attack the Weinreb amide fragment 2.14.  This was performed on ten-milligram scale with 
a yield of 46%.   
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Scheme 16 
 
Six milligrams of the protected enone product 2.29 was subjected to acidic deprotection 
conditions (Scheme 17) using a mixture of tetrahydrofuran and aqueous hydrochloric acid at 
room temperature.  This last step proceeded slowly, but it was ultimately successful with 95% 
yield.  
Scheme 17 
 
2.11 Future Work           
 The construction of the proposed SV-6 structure has been completed to supply six 
milligrams for spectroscopic analysis and biological assay.  This material was transferred to the 
original investigators and will be compared to the spectra of the natural product.  The initial 
synthesis can be repeated to generate more material if needed for biological analysis.  In the 
event that the structures do not match, computational studies in combination with synthesis of 
isomers may be used to ascertain the configuration of the natural product
79
.  The potential for 
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diversity is an advantage of the second route that cannot be understated (Figure 14).  By using 
the same experimental procedures outlined herein, it is possible to generate countless isomers 
and unnatural analogs for the study of structure-activity relationships
80
.  The figure below shows 
just a few examples of compounds that can be generated by following these procedures but only 
substituting commercially available reagents.  Different enantiomers of Roche ester, 
pseudoephedrine diisopropyl tartrate (DIPT) can be used to influence the stereochemistry of the 
branched alkyl units (C-4 and C-6) and hydroxyl group (C-10 and C-11).  Different groups can 
be substituted at the C-4 position by use of different pseudoephedrine amides.  In this case, any 
number of anhydrides or acyl chlorides may be used to generate chiral amides in a single 
chromatography-free step.    Substitution of different groups can be added to C-3 position but 
replacing the isopropyllithium used for SV-6 with other organollithiums or Grignard reagents.      
 
Figure 14 
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III. CHEMICAL MODIFICATION OF REPIN 
  
3.1 Rhaponticum repens and Toxic Parkinsonism in Horses 
Russian knapweed or Rhaponticum repens (L.) Hidalgo of the family Asteraceae is the 
most recognized toxic plant contributor to equine nigropallidal encephalomalacia (also called 
toxic equine parkinsonism or “chewing disease”)81.  It has been previously referred to as 
Centaurea repens or Acroptilon repens. It is an invasive perennial plant species that is native to 
Eurasia but was brought to the United States in the early 1900’s.  It bears broad, oblong lower 
leaves leaves but toothed upper leaves.  The plant has and thin, stiff, pithy stems and stands 
erect, with the potential to grow up to one meter in height.  It bears urn shaped flowers that vary 
from pink to purple in color.  Once past maturity, these flowers fade into a straw color.  The 
seeds are also a straw or ivory color, oval in shape and 2 mm wide, 4 mm long and 1 mm thick 
(Figure 15).  Both the seeds and the stems are covered with fine hairs.  The plant has invasive 
character, leading to infestations in fields.  In the case where they do not entirely dominate an 
area to the point of monoculture, they can suppress the growth, size and number of plants it 
shares location with.  According to Watson as of 1980 they were capable of reducing grain 
density by 28-75%.  Plant extracts of R. repens have demonstrated allelopathic inhibitory effect 
of crop plants.  It seems to only require tillable soil, with some preference for saline or alkaline 
soils.  Russian knapweed is robust in its ability to survive without regard for other species of 
plant it is surrounded by (or lack thereof). It is this co-habitation with crop plants that is thought 
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to be responsible for its spread south and east, most likely from sale and distribution of hay 
contaminated with Russian knapweed seeds
82
.  The majority of these R. repens traits are 
common to Centaurea solistialis, with some difference in flower morphology.  For instance, 
C.solistialis has yellow flowers with sharp thorns extending from the base of the buds.   
 
Figure 15 Images of Rhaponticum repens (A) full plant (B) seeds (C) flowering tops in hand for scale (D) 
single flower
83
. 
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Figure 16 Distribution of Russian knapweed in the United States
83 
 
3.2 Toxic Effects of R. repens  
Cordy first reported that horses in the northern and central region of California were beset 
by a neurological disorder linked to the consumption of Russian knapweed and yellow star 
thistle.  It had been previously identified by local veterinarians as “chewing disease” or “yellow 
star thistle poisoning”65.  According to this initial report, there was always a sudden onset to the 
symptoms which included impairment of eating and drinking.  Some animals displayed complete 
inability to eat or drink while others might be “dropping feed from the mouth, [partially unable] 
to move the material back to the molars, or some difficulty swallowing”65.  Eating was typically 
affected more than drinking, hence the name “chewing disease”.  Also common was a fixed 
expression and tongue protruding from between incisor teeth which indicated paralysis of the 
42 
 
facial musculature.  Of note were changes in the behavior of horses, they often stood motionless 
or with a drowsy pose.  This was accompanied by aimless, abnormally slow or awkward walking 
which deteriorated to a wobbling or shuffling gait in later stages.  Initially a parasitic or viral 
cause of these symptoms was considered, but further anatomical investigation of horse tissues 
were ruled inconsistent with either hypothesis.  Eventually, this constellation of movement 
impairments combined with the presence of neuronal legions was termed “equine nigropallidal 
encephalomalacia” (ENE)84.  Despite the sudden onset of ENE, animals must consume 59-71% 
of their body weight before these symptoms manifest.   
 
3.3 Structure of SQLs from R. repens 
Due to the allelopathic and toxic activity of the R. repens plant, it has been the target of 
thorough phytochemical examinations.  The focus of this work is on terpenes although alkaloids, 
flavonoids, tannins, polyacetylenes and glycosides have all been isolated from the plant.  Studies 
of volatile components by Buttery and Binder demonstrated that SQLs comprise between 50% 
and 90% of the plant material by weight.  Specifically, there were 58% of aggregate volatiles in 
buds, 56% in blooms, and over 89% in leaves and stems
85,86
.  In a series of studies led by Stevens 
for the USDA,  a number of SQLs were identified from Centaurea solstitialis, particularly 
noteworthy among these structures are the presence of many chlorohydrins (3.3, 3.7, 3.8, 3.11) 
products from the opening of epoxides and picrolide 3.2, which bears p-hydroxybenzoyl 
methylene moiety on 4-position of the A ring (Figure 17)
87
.                  
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Figure 17 
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3.4 Collection of Plant Material and Isolation of Repin  
The plant material (R. repens) was collected by Dr. Gunatilaka (September 2002) and Dr.  
Rimoldi (July-August 2004 and May 2007) in Riverside, California.  It was collected in a 
somewhat developed semiurban area (near a golf course).  This location was selected based on 
previous positive identification and collections on the same plot of land.  Mature flowering 
plants were collected and dried and voucher specimens were deposited at the University of 
California at Riverside herbarium.   
A variety of methods have been used for isolation of SQLs from Centaurea species.  
These approaches involve the use of many different combinations of solvents and stationary 
phases or treatment of extracts with lead (II) acetate to facilitate removal of chlorophyll
88
.  
Rimoldi et al. have used various methods
89
.   
Method A 
The first method begins with hexane extraction for 24 h, then two acetone extractions for 
2 h each.  These acetone extracts were combined, evaporated and subjected to vacuum liquid 
chromatography (VLC) using a ethyl acetate/hexane gradient (30% ethyl acetate increasing to 
100%).  Following analysis and combination of subfractions, repin was isolated after another 
round of column chromatography.  
Method B 
Aerial plant material was macerated in hexanes for 24 h followed by two 48 h acetone 
extractions.  This extract was evaporated then reconstituted in anhydrous ethanol.  The ethanolic 
solution was slowly treated with a 5% aqueous solution of lead (II) acetate which formed a 
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precipitate that was stirred for 24 h before vacuum filtration.  This filtrate was evaporated and re-
extracted into anhydrous dichloromethane.  Extracts were dried over sodium sulfate, evaporated 
and subjected to VLC using a ethyl acetate/hexanes gradient (50% ethyl acetate increasing to 
100% followed by 60:40 isopropanol/ethyl acetate).  Subfractions from the 75:25 EtOAc-
hexanes were rich in repin and were subjected to recrystallization from ethyl acetate.         
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3.5 Biosynthesis of Sequiterpenes 
There is a vast array of terpenoids present across the plant kingdom whose structures 
range from simple to incredibly complex.  All these structures can be traced back to only a 
couple of simple biosynthetic intermediates- either mevalonic acid (MVA) and methylerythritol 
phosphate (MEP)
57
. 
 
Figure 18 
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The conventional names for these structures fall into terms determined by the size of their carbon 
skeletons.  Some discrepancy between named category and final carbon count may be attributed 
to loss of carbons by decomposition of a larger terpene structures or late-stage addition of small 
units.   The overall structure is represented by (C5)n.  With this system, the family of terpenes is 
subclassified as hemiterpenes (C5), monoterpenes (C10), sesquiterpenes (C15), diterpenes (C20), 
sesterterpenes (C25), triterpenes (C30), and tetraterpenes (C40), followed larger isoprene polymers 
such as rubbers (Figure 18).  These units are rarely seen as simple linear polymers and instead 
often undergo a number of oxidations, rearrangements and combinations with intermediates of 
acetate, peptide and shikimate pathways to form their isolated products
57
. 
MVA is formed by the fusion of three molecules of acetyl-coenzyme A.  The eventual 
decarboxylation and dehydration of mevalonic acid diphosphate (MVAPP) yields isopentyl 
phosphate (IPP).  Figure 19 displays enzyme-mediated isomerization of IPP to DMAPP creates 
the system where SN1-mediated loss of diphosphate anion creates stabilized cation that will 
serve as the electrophilic partner to the nucleophilic terminal alkene of IPP.  These two initially 
combine to form geranyl diphosphate (GPP), which can now act as an electrophile to another IPP 
unit
57
.   
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Figure 19 
This iterative process continues for another cycle and the result is farnesyl diphosphate (FPP).  It 
is important to note that stereospecific proton loss is responsible for E-stereochemistry of the 
double-bond.  This stereochemical outcome is an important factor in the subsequent creation of 
intramolecular carbon-carbon bonds on the E,E- farnesyl scaffold.  FPP is a key intermediate in 
the formation of multicyclic terpenes, including the sesquiterpene lactones.  Loss of diphosphate 
from farnesyl-PP generates a cation facilitating E1 elimination to form (+)-germacrene A.  This 
is followed by a series of enzymatic oxidations using NADPH, to generate parthenolide (Figure 
20).  
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Figure 20: Biosynthesis of medicinally valuable parthenolide 
 
Parthenolide is a secondary metabolite with well-known cytotoxic activity
90
.  But 
parthenolide represents only one example of the potential products produced from the germacryl 
cation intermediate.  Figure 21 below shows the diversity of structures generated from three 
products of the germacryl cation intermediate.  Fermacrene, costunolide and parthenolide serve 
as the biosynthetic precursor to many biologically active sesquiterpenes including repin, the 
subject of our group’s research.  What we understand of the biosynthesis of terpenes is the 
product of many years of study using isotopic labeling and biochemical experimentation
57
.  
However, the exact path of repin’s synthesis in Centaurea solstitialis remains unclear. 
50 
 
 
Figure 21 Structural diversity generated from germacrene, parthenolide and costunolide 
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3.6 Modification to Repin 
There are numerous cytotoxic compounds in R. repens, but the exact toxin and mode of 
action are not entirely understood.  Repin 3.15 is prevalent in the plant and a definite contributor 
to neurotoxicity but outward indicators of degeneration are not completely consistent with the 
established models of Parkinson’s disease.  The primary aim of this work has been to create 
derivatives of repin to act as molecular probes to determine its protein target.  
Preliminary work in the Rimoldi lab has identified the portions of the molecule that seem 
to contribute to the neurotoxic activity and those that do not (Figure 22)
89
.  The next stage of our 
investigation is to create a biotin-linked conjugate which will be used to identify the molecular 
target(s) of repin. 
 
Figure 22   
 
The early work focused on using esterification reactions to directly bind the secondary 
alcohol of repin to the carboxylic acid of biotin.  Unfortunately due to the multiple sensitive 
electrophic groups of repin, these attempts at esterification were met with failure.  The primary 
issue with all these approaches was that nucleophilic reagents can attack repin directly at these 
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sites.  Non-nucleophilic bases can catalyze intramolecular attack while acidic conditions 
facilitate carbocationic rearrangements.   
 
Table 1 
 
However, esterification using the smaller acrylic acid 3.18 was successful.  This now provided a 
handle for olefin cross-coupling chemistry (Scheme 18).  A complementary biotin allyl 3.19 
amide was produced successfully, but the Grubbs cross-coupling attempts did not work.     
53 
 
Scheme 18 
 
 
The Huisgen 1,3-dipolar cycloaddition (Scheme 19) is known to be extremely 
chemoselective and performs well in complex mixtures including biological systems
91
.  The 
regiochemistry can be controlled depending on whether copper or ruthenium is used to catalyze 
the reaction.  The system we planned to use is Cu(I) catalyzed alkyne-azide cycloaddition 
(CuAAC) as it creates the stable triazole with the linker and repin scaffold oriented trans to from 
each another.  
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Scheme 19 
 
3.7 Alternate Route: Nicholas and Click Cycloaddition 
Recently, a modification of the Nicholas reaction has been reported by the groups of 
Harki and Brummond in which the nucleophile is the limiting reagent, reducing the capacity for 
nucleophilic attack onto reactive scaffolds
92
. This method has shown utility in attaching alkyne 
ligation handles onto serine alcohols, cysteine thiols, tyrosine phenols, pyrrolidine nitrogens of 
proline, as well as amino and carboxy groups of amino acids. Sesquiterpene lactones bearing 
similar functionalities such as Melampomagnolide B 3.23 and a guaianolide analog 3.25 (Figure 
23) have also been successfully modified using this method.  One foreseeable problem with this 
approach is the possible steric interference of adjacent epoxide.   
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Figure 23 Examples of sesquiterpene lactones screened by Harki and Brummond
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3.8 Nicholas Reaction: Success and Failure 
The Nicholas reaction was attempted on repin as a substrate and after many failed 
attempts, we produced the propargyl ether product 3.21 of interest.  Over two steps, the yield was 
approximately 15% (10mg), and was never fully purified away from a co-eluting impurity 
(Scheme 20).  The reaction was repeated at larger scale in order isolate enough material for the 
CuAAC reaction with biotin-azide and subsequent biological studies.  In these subsequent 
reactions, it never fared better in terms of yield or purity.  The addition of the propargyl group 
was evident on NMR and high-resolution mass spectral data matched that of our intended 
product.     
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Scheme 20 
 
3.9 Copper-catalyzed Alkyne-Azide Cycloaddition 
  As the supply of isolated repin dwindled, the limited amount of the propargylated 
material that remained was taken forward for CuAAC reactions (Scheme 21).  These 
cycloadditions proved more challenging than expected (Table 2).  The stability of the repin 
scaffold under acidic CuAAC conditions was first tested using repin instead of the propargylated 
material.  Following this, the reaction was attempted under various conditions (~1mg scale) with 
varying success before scaling up.   
Scheme 21 
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The reaction yields were not quantified, only monitored by TLC and ESI-MS for consumption of 
starting materials and formation of product 3.28.  When using CuI as a copper (I) source, 
transition of solution from clear or yellow to bright blue corresponded with the consumption of 
starting material. Despite this useful indicator of reaction progress, this reaction did not behave 
in the same manner when scaled up.  This is likely due to inaccuracy of measuring reagents in 
those test reactions.  After moving to CuSO4/ sodium ascorbate conditions, the reaction worked 
well and scale up was more successful.  
 
Table 2 
 
It was immediately obvious that the product of interest had almost the same retention 
factor on silica as the biotin-PEG3-azide starting material 3.27.  The material was subjected to 
preparative thin layer chromatography, but the material produced was not pure.  This material 
was subsequently subjected to HPLC, but the two peaks were not separable, possibly due to the 
weak UV absorbance of the components of the mixture in the range of the UV detector.  The 
same material was subjected to LC-MS analysis, where product was clearly identified. However, 
the purity was approximated to be 30%-50%, with uncertainty due to variable levels of 
ionizability between components of the mixture.  NMR analysis of the product showed presence 
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of biotin, polyethylene glycol and repin sections of the molecule but also with areas of 
unidentifiable impurities.    
 
3.10 Additional Target Screens for Repin 
 The narrow goal of this project was project was to create a biotin tagged version of repin.  
The overarching goal of this project has been to better understand the molecular mechanisms at 
work behind repin’s unique toxicity.  The failure to produce analytically pure biotinylated repin 
is only one aspect of a project in which there were some noteworthy revelations.  Large scale 
screening of protein targets has become increasingly practical and multiple lines of investigation 
were pursued.  Repin was submitted multiple different screens including a broad, multiplexed 
serine protease assay (ENPLEX) and a panel of kinases (KinomeScan)
93,94
.  Despite the 
possibility that a compound bearing multiple electrophilic sites may not show selectivity against 
enzymes, this was not the case.   
 Repin was screened against a total of 158 enzyme targets and only showed activity at two 
different targets (APPENDIX I).  Of the 158 targets, 119 were serine hydrolases and 39 were 
kinases.  Repin showed no interaction with the set of serine proteases that included HTRA2, 
which is correlated with essential tremor and PD
95
.  Of the 39 kinases selected based on literature 
support correlating them to dopaminergic signaling, mitophagy, PD, or neurodegeneration, only 
two targets were to be inhibited: GRK3 and LKB1.  LKB1 regulates the ability of presynaptic 
mitochondria to clear calcium by regulating the density of a Ca
2+
-selective ion channel on 
mitochondria’s inner membrane.  This LKB1-regulated calcium clearing also controls 
neurotransmitter release from excitatory synapses on cortical axons
96
.  LKB1 demonstrates a role 
59 
 
in autophagy, a pathway that is the only route to degrade protein aggregates that cannot be 
processed by the proteasome.  This autophagy pathway is of particular importance in autosomal 
dominant PD (α-synuclein and LRRK2 associated)97.  The other hit, GRK3, is a kinase that 
phosphorylates dopamine G protein-coupled receptors following activation by a ligand.  This 
activation creates a high-affinity interaction between the G proteins and arrestin- a feedback loop 
that leads to deactivation and receptor degradation.  The interplay of GPCRs, G proteins, arrestin 
and GRKs regulates striatal dopamine signaling and can lead to dyskinesia that is typical of 
PD
98
.  While much remains to be understood, there are now two previously unreported protein 
targets for repin to guide further studies.  Almost as important are the negative results from the 
119 proteases targets, highlighting the incredible selectivity that is possible with sesquiterpene 
Michael acceptors such as repin
99
.               
 
3.11 Future Work 
 Studying the molecular mechanism of repin’s toxicity has been an object of our attention 
for some time.  Despite not purifying a pure biotinylated product, this work represents a way 
forward.  Another path considered but never attempted was a modification of repin to the azide.  
This seemed much more risky due to the nucleophilicty of the azide anion involved, but it may 
be facilitated by activation with Schwartz’s reagent/ zirconocene hydrochloride. 
Hydrozirconation can be followed with displacement with a nucleophile, such as halogen or 
azide (Figure 24).  This may be further complicated by iodination prior to azide substitution. 
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Figure 24 
The modification of repin is all predicated on the amount of natural product available to attempt 
said modifications.  Further synthetic studies would all require more repin to be isolated from 
Knapweed extracts or plant material.  Purification of the biotin-repin from its mixture may be 
enabled by semi-preparative LC-MS. 
 Biological studies have failed to produce a complete picture of how repin manifests its 
toxicity (APPENDIX I).  A streptavidin pulldown assay may still provide a missing piece of 
evidence to tie some of these activities together.  It is possible that such an assay using the crude 
biotinylated material could yield this information if HRMS-based proteomic analysis could 
differentiate between various covalent adducts.   
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EXPERIMENTAL 
 
 
General 
All reagents were purchased from Sigma-Aldrich, Acros Organics or Alfa Aesar.  
Chromatography solvents were purchased as certified A.C.S. grade from Fisher Scientific.  
Acros extra dry solvents over molecular sieves were used for all reactions.  Thin layer 
chromatography (TLC) was performed on Merck silica gel 60 F254 aluminum sheets.  To 
visualize TLCs, both UV light and staining reagents (phosphomolybdic acid, ceric ammonium 
molybdate, and potassium permanganate) were used.  Flash chromatography was performed 
using standard grade silica gel particle size of 32-62 μm from Sorbent Technologies.  1H NMR 
and 
13
C NMR spectra were recorded using Bruker 400 or 500 MHz instruments.  Low resolution 
mass spectral data was acquired using Waters ZQ with electrospray ionization (ESI) conditions.  
Optical and specific rotation were measured using a Rudolph Autopol IV polarimeter.     
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This method was adapted from a procedure by Myers et al
68
.  A 3000ml flame dried three neck 
with flask with magnetic stir bar was removed from oven and flame dried under vacuum and 
filled with argon three times.  After cooling, (S)-3,3-dimethyl-2-morpholinobutan-1-ol ligand 
(1.54 g, 8.24 mmol, 0.02 eq.) was added followed by 300 mL of anhydrous hexane.  After ligand 
was fully dissolved in hexanes, the flask was cooled to 0
o
C.  At this point, a solution of Et2Zn in 
hexanes (800 mL, 1.0 M, 800 mmol, 1.94 eq.) was added via cannula, immediately causing a 
dense white vapor to form the receiving vessel.  This solution was stirred for 30 min at 0
o
C, then 
crotonaldehyde (33.6 mL, 412 mmol, 1 eq., freshly distilled) was added over 90 minutes by 
syringe pump.   
After 3 h, magnetic stir bar was carefully removed and stirring was changed to an overhead, 
mechanical apparatus.  Ice-chilled HCl (850 mL, 3 M) was added dropwise via pressure 
equalizing addition funnel.  A thick white precipitate formed during the addition, but eventually 
dissolved near the end of the quenching step.  The entire biphasic mixture was added to a 4000 
mL separating funnel and layers were separated.  The aqueous layer was extracted (2 x 500 mL), 
then combined and washed with brine (500 mL).  The washed solution was dried over Na2SO4 
and filtered.  This bulk volume of the filtrate was removed by rotary evaporator at a pressure of 
~40 Torr and temperature of 10
o
C.  The clear oil concentrate was transferred to a 250 mL round-
bottom flask using diethyl ether to quantitate transfer.  Remaining solvent was removed at 
atmospheric pressure using a short-path distillation head and heating at 90
o
C (oil bath).  This 
bath was then removed; distillation flask was cooled to 23
o
C.  Pressure was then lowered again 
to ~40 Torr and receiving flask was placed in a ice-water bath.  Distillation resumed as the oil 
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bath reached 90
o
C and product distilled at a temperature of 
o
C at ~40 Torr.  The resulting clear 
liquid weighed 31 g (yield 75%).  Enantiomeric excess was not determined as the NMR data 
showed presence of major impurities.  Side product produced was consistent with literature 
values for the constitutional isomer hex-3-en-2-ol
100
.       
1
H NMR (400 MHz, CDCl3) δ 5.68 – 5.53 (m, 2H), 5.50 – 5.36 (m, 1H), 4.20 (p, J = 6.4 Hz, 
1H), 3.89 (q, J = 6.6 Hz, 1H), 2.07 (s, 1H), 1.99 (p, J = 7.4 Hz, 1H), 1.65 (dd, J = 6.4, 1.5 Hz, 
3H), 1.48 (ddt, J = 16.9, 13.9, 7.2 Hz, 2H), 1.19 (d, J = 6.3 Hz, 2H), 0.94 (t, J = 7.5 Hz, 2H), 0.84 
(d, J = 14.9 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 134.07, *133.16, *132.33, 126.62, 74.33, *68.73, 30.03, *25.03, 
*23.32, 17.56, *13.34, 9.69. (asterisks denote impurity)  
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Acetal-protected vinyl iodide (“Fragment A”) was produced wholly in accord with the published 
synthesis by Cossy
58
. Spectra were found to be in agreement.  
 
(R,R)-Pseudoephedrine propionamide was produced wholly in accord with the published 
synthesis by Myers
73
. Spectra were found to be in agreement. 
 
(1R,2S)-1-cyclohexyl-2-morpholino-2-phenylethan-1-ol (“Ligand 1”) was produced wholly in 
accord with the published synthesis by Nugent
67
. Spectra were found to be in agreement.  
 
(S)-3,3-dimethyl-1-morpholinobutan-2-ol (“Ligand 2”) was produced wholly in accord with the 
published synthesis by Hayashi
101
. Spectra were found to be in agreement.   
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Using an adapted method from Sherman, starting material iodide was dried azeotropically with 
benzene twice before use
56
.  To an oven-dried 300 mL round bottom flask was added lithium 
chloride (6.69 g, 157.73 mmol, 12eq.).  This vessel was then iteratively flame dried under 
vacuum and back-filled with argon gas for five cycles.  While cooling, an oven-dried 50ml pear-
shaped flask was charged with pseudoephedrine propionyl amide (4.65 g, 21.03 mmol, 1.6 eq.).  
After careful heating under vacuum and backfilling with argon for three cycles followed by 
cooling, dry THF (40ml) was added via cannula.   
50mL was then added to the 300mL flask containing lithium chloride and the resulting slurry 
was allowed to stir for 30 minutes.  This flask was cooled -78
o
C.  Lithium diisopropylamine 
solution (21ml, 42.06 mmol, 3.2 eq. of ACROS, 1.7M in THF/n-heptane/ethylbenzene) was 
added and maintained at -78
o
C.  At this time, the contents of the 50mL flask were transferred via 
cannula to the 300mL flask.  The resulting solution was stirred for 1 h at -78°C, 30 min at 0°C, 
and 10 min at RT before it was cooled to 0 °C.  Protected alkyl iodide 2 was dissolved in 15mL 
THF and added dropwise followed by an 8mL THF wash.  Solution was allowed to warm to 
room temp and stirred for 12 h.  The reaction was quenched with saturated NH4Cl (60 mL), and 
poured into a 250mL separatory funnel containing H2O (100 mL), and the aqueous layer was 
extracted 3x with CH2Cl2. The combined organic extracts were washed with brine and filtered 
through a sodium sulfate plug, which was then rinsed 2x with CH2Cl2. Concentration and flash 
chromatography: EtOAc/Hexanes (3:7) afforded a white, waxy solid (4 g, 9.81 mmol, 75% 
yield).  Spectral data matched that of previously published synthesis
72
. 
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To a 100mL flame-dried round bottom flask under argon was added 20ml dry THF.  The flask 
was cooled to 0
o
C.  Lithium diisopropylamine solution was added (8.1 mL, 16.2 mmol, 4.4 eq. of 
ACROS, 1.7M in THF/n-heptane/ethylbenzene) and allowed to stir 3 min.  Borane-ammonia 
complex (468 mg, 14.7 mmol, 4 eq., 97% Sigma-Millipore) was added quickly in one portion.  
Solution was stirred 15 min at 0
o
C, then stirred 15 min at RT, then returned to 0
o
C.  The amide 
(1.5g, 3.7 mmol, 1 eq.) dissolved in 10 mL THF and added followed by a 10 mL THF wash.   
Solution was warmed to RT with a water bath, stirred 4.5 h then cooled to 0
o
C and cautiously 
quenched with 40 mL (chilled) 1N HCl then stirred at RT for 30 min.  Reaction mixture was 
added to separatory funnel and extracted 4x 50mL Et2O.  Organic phase was washed with 50mL 
1N HCl, 50mL 1M NaOH, and 100mL brine.  Organic phase was dried over MgSO
4
 and solvent 
was removed under reduced pressure (rotovap bath temperature >10
o
C.)   Flash chromatography: 
Et2O/Hexanes (4:6) afforded a clear liquid (780 mg, 3.16 mmol, 86% yield).   Product material 
matched previously published spectroscopic data
55
.  
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To a solution of alcohol (628 mg, 2.55 mmol, 1 eq.) in pyridine (2.5 mL) was added para-
toluenesulfonyl chloride (971 mg, 5.1 mmol, 2 eq.) and DMAP (47 mg, 0.382 mmol, 0.15 eq.) at 
0°C.  
The reaction mixture was allowed to warm and was stirred for 3 h at RT before it was quenched 
with HCl (1.0 N, 7 mL) and extracted with ethyl acetate (2× 10 mL).  
The combined organic extracts were washed with saturated Na2CO3 solution (2 × 7 mL) and 
brine (1 × 7 mL), dried with anhydrous Na2SO4 and filtered. Concentration and flash 
chromatography: (pentane/ethyl acetate, 9:1) afforded 1.01 g of tosylate as clear oil (99%). 
Spectral data matched that of previously published synthesis
102
. 
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To a flame-dried, argon filled flask was added CuI (1.62 g, 8.51 mmol, 3.3 eq.), followed by two 
vacuum-argon cycles.  Flask was cooled to 0 °C, 15mL of dry Et2O was added, followed by 
25mL a 0.7 M solution of isopropyllithium (ACROS in pentanes; 17.27 mmol, 6.7 eq) via 
cannula.  
After 45 min, the mixture was cooled to -78°C and treated with tosylate (1.03 g, 2.57 mmol, 1 
eq.) in 3 mL of dry Et2O, followed by 3ml Et2O wash. After 3 hr, the reaction mixture was 
quenched with 50mL of a 4:1 mixture of NH4Cl (sat.)/NH4OH (29%) at 0 °C, extracted with 
Et2O, washed with brine and dried with MgSO4. Concentration and flash chromatography: 
(100% hexanes) afforded 525 mg of alkylated product as clear oil (75%). 
1
H NMR (CDCl3, 400 MHz) δ 3.45 (dd, J = 9.7, 5.1 Hz, 1H), 3.33 (dd, J = 9.7, 6.7 Hz, 1H), 1.72 
– 1.51 (m, 3H), 1.34 – 1.20 (m, 2H), 1.14 – 1.05 (m, 1H), 1.00 – 0.81 (m, 22H), 0.04 (s, 6H). 
13
C NMR (CDCl3, 101 MHz)  δ 68.46, 46.91, 41.83, 33.27, 29.91, 27.91, 26.13, 26.13, 26.13, 
25.38, 23.86, 22.2, 20.70, 17.82, -5.1, -5.20. 
HRMS: Calculated [M+Cs]+ calculated for C16H36OSiCs: 405.1590 m/z; found 405.1793 m/z. 
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To a stirred solution of protected alcohol in 3.5 mL THF at 0
o
C was added tetrabutylammonium 
fluoride solution (ACROS 1M in THF; 2.5 mL, 2.5 mmol, 1.9 eq.).  The cooling bath was 
removed and the reaction was stirred at RT overnight. Concentration under reduced pressure and 
flash chromatography (100% hexanes to 100% CH2Cl2; Rf 0.36 in 100% CH2Cl2) afforded 
188mg of product (90%).  Spectral data matched that of previously published synthesis
60
.   
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To a solution of alcohol in CH3CN (8 mL) and phosphate buffer (8mL, pH 7.0, 100 mM) were 
subsequently added NaClO2 (310 mg, 3.42 mmol, 6.3 eq.), NaClO (1.55 mL; store-bought 
Clorox brand, 8.5% chlorine content) and TEMPO (7 mg, 0.046 mmol, 0.09 eq.) at room 
temperature. After being stirred for 1 h, the pH value of the reaction mixture was adjusted to 3 
with 2M HCl.  
Volatiles were removed in vacuo; the aqueous residue was extracted with diethyl ether (2 x 30 
mL). The combined organic layers were washed with brine (30 mL), dried over anhydrous 
Na2SO4, concentrated in vacuo.  Flash chromatography: 15% ethyl acetate/hexanes (Rf: 0.34, 
20% ethyl acetate/ hexanes) afforded a clear, liquid product with a minty aroma (72 mg, 77% 
yield).  
1
H NMR (CDCl3, 400 MHz): δ 10.17 (brs, 1H), 2.67 – 2.62 (m, 1H), 1.79 – 1.69 (m, 2H), 1.61 – 
1.56 (m, 1H), 1.24 (d, J = 6.5 Hz, 3H), 1.21 – 1.01 (m, 4H), 0.98 – 0.84 (m, 11H). 
13
C NMR (CDCl3, 101 MHz) δ 182.79, 45.49, 40.30, 36.37, 27.09, 23.91, 22.19, 21.21, 18.72, 
16.81. 
HRMS: Calculated [M-H]+ calculated for C10H20O2: 171.1385 m/z; found 171.1359 m/z.  
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To an ice-cooled and stirred solution of trimethylheptanotic acid (57 mg, 0.33 mmol, 1 eq.), was 
added N,O-dimethylhydroxylamine hydrochloride (34 mg, 0.35 mmol, 1.05 eq), and 
triethylamine (0.04 mL, 0.35 mmol, 1.05 eq) in DMF (6mL) HOBt (51 mg, 0.38 mmol, 1.15 eq) 
and 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (73 mg, .38 mmol, 1.15 eq) 
were added.  The mixture was stirred at room temperature for 15 h.  
At this point, reaction was diluted with toluene, washed with 1N aq. HCl followed by saturated 
NaHCO3, and brine, dried over Na2SO4, and concentrated under reduced pressure.  Flash 
chromatography: 1:9 ethyl acetate/hexanes to 1:4 ethyl acetate/hexane yielded 32 mg of amide 
(45% yield).  
1
H NMR (CDCl3, 400 MHz): δ 3.69 (s, 3H), 3.17 (s, 3H), 1.78 – 1.59 (m, 2H), 1.50 – 1.37 (m, 
1H), 1.15 – 0.89 (m, 7H), 0.83 (m, 9H). 
DEPTQ-135 NMR (CDCl3, 101 MHz) δ 61.55, 46.92, 41.83, 32.77, 28.51, 25.25, 25.25, 23.53, 
22.39, 20.25, 18.31. 
HRMS: Calculated [M-H]+ calculated for C12H25NO2: 214.1807 m/z; found 214.1966 m/z.  
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To a stirring solution of vinyl iodide (10 mg, 0.046 mmol, 1 eq.) in dry Et2O (0.75mL) at -78
o
C 
was added t-BuLi (ACROS 1.7M in pentane) dropwise.  After stirring 45 minutes at -78
o
C, a 
solution of amide (30 mg, 0.102 mmol, 2.2 eq.) in 0.5ml Et2O was added quickly followed by a 
0.5mL rinse.  Reaction mixture was then warmed to -42
o
C (acetonitrile and dry ice bath) and 
stirred 1hr.   
After this time, the reaction mixture was diluted with Et2O and quenched by addition of saturated 
aqueous NH4Cl solution at 0°C.  The solution was extracted with Et2O; the organic layers were 
combined, washed with brine, dried over MgSO4 and concentrated under reduced pressure.  
Flash chromatography: 1:9 diethyl ether/pentanes afforded a clear liquid product (7 mg, 46%). 
Note: Some solvent signals and dibutylhydroxytoluene (from diethylether) were present in NMR 
spectra.  Due to the unknown volatility of this compound, it was only exposed to high-vacuum for 
a brief period.   
1
H NMR (CDCl3, 500 MHz): δ 6.78 (d, J = 15.5 Hz, 1H), 6.43 (d, J = 15.5 Hz, 1H), 3.82 (t, J = 
6.6 Hz, 1H), 2.81 (dt, J = 13.6, 6.8 Hz, 1H), 1.71 – 1.60 (m, 3H), 1.53 – 1.49 (m, 5H), 1.45 – 
1.37 (m, 11H), 1.25 (s, 3H), 1.13 – 0.92 (m, 11H), 0.88 – 0.79 (m, 11H).  
13
C NMR (CDCl3, 126 MHz) δ 203.82, 146.93, 127.26, 86.24, 77.16, 46.88, 42.79, 41.40, 28.47 
(2C), 28.28, 26.62, 25.26 (2C), 24.83, 23.59, 23.49, 22.25, 17.32, 11.40. 
HRMS: Calculated [M+Cs]+ calculated for C20H36O3Cs: 457.1719 m/z; found 457.1695 m/z. 
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To a 20 mL scintillation vial was added 5 ml of 1:1 THF/1N HCl and stirred at RT for 18 h.  
After 24h, 60 µL 3N HCl was added and reaction was monitored. After 24 additional hours, 40 
µL 3N HCl was added and the reaction was monitored for disappearance of starting material.  
After 24 additional hours, the reaction was quenched with NaHCO3. This mixture was extracted 
with ethyl acetate (6 x 5 mL) and washed with brine.  Flash chromatography: CH2Cl2 to 1:6 ethyl 
acetate/CH2Cl2 yielded 5 mg of product (95% of theoretical yield). 
1
H NMR (CDCl3, 400 MHz): δ 6.86 (d, J = 15.6 Hz, 1H), 6.48 (d, J = 15.6 Hz, 1H), 3.4 (dd, 8, 4 
Hz, 2H), 2.81 (dt, J = 13.6, 6.8 Hz, 1H), 2.56 (s, 1H), 2.02 (s, 1H), 1.75 – 1.50 (m, 6H), 1.50 – 
1.39 (m, 2H), 1.34 (s, 3H), 1.27 (d, J = 14.4 Hz, 1H), 1.08 (d, J = 6.9 Hz, 3H), 1.00 (t, J = 7.4 Hz, 
3H), 0.88 – 0.78 (m, 10H). 
13
C NMR (CDCl3, 101 MHz) δ 204.10, 148.02, 126.90, 79.72, 75.71, 46.83, 42.87, 41.17, 28.44, 
25.27, 25.16, 24.92, 23.57, 22.28, 20.21, 17.37, 11.14. 
HRMS: Calculated [M+Cs]+ calculated for C17H32O3Cs: 417.1406 m/z; found 417.1575 m/z. 
[α]D
21
= +13.5 (c 0.67, CHCl3) 
IR (neat) 3373, 2958, 2929, 1675 
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Prepare silica column for flash chromatography before or while starting reaction procedure.  
Remove round-bottom flask from the oven, fill with argon, cover and cool to room temperature 
on bench.  Dissolve 16μL propargyl alcohol in 1.5mL of anyhdrous CH2Cl2.  Weigh and transfer 
cobalt carbonyl into a separate flask.  Add propargyl alcohol/CH2Cl2 solution to cobalt carbonyl 
containing flask and stir at RT for 1.5 hours.   Dissolve 50mg of repin into 2.3mL anhydrous 
CH2Cl2.  Cool reaction flask to 0
o
C. Add repin solution followed by dropwise addition of BF3-
etherate.  Stir only 10 minutes, add 1ml saturated NaHCO3. Stir one minute before addition of 
(4ml) water.  
Extract 3x with CH2Cl2. Dry on MgSO4, filter and evaporate onto Celite under reduced pressure.  
Separation on silica (0% to 30% gradient of ethyl acetate/hexanes).  Main spot elutes at 30% 
ethyl acetate, and solvent is immediately removed before carrying Co2(CO)6-alkyne intermediate 
rapidly to the next step.  To 15mg cobalt complex is added 1.5 mL acetone is added 60mg of 
ceric ammonium nitrate.  Reaction is allowed to stir 10 minutes (or until consumption of starting 
material is complete). The reaction was diluted with distilled water and diethyl ether. The 
mixture was transferred to a separatory funnel. The layers were separated and the aqueous layer 
was extracted with diethyl ether (3x). The combined organics were dried over magnesium 
sulfate, filtered, and concentrated under reduced pressure rotary evaporation.  Yields over two 
steps ranged between 5%-15%.      
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1
H NMR (CDCl3, 400 MHz) δ 6.21 (d, J = 3.5 Hz, 1H), 5.54 (d, J = 3.1 Hz, 1H), 5.21 – 5.09 (m, 
3H), 4.94 (s, 1H), 4.18 (d, J = 2.4 Hz, 2H), 3.34 (d, J = 4.3 Hz, 1H), 3.17 (dd, J = 14.4, 5.0 Hz, 
3H), 2.81 (d, J = 5.9 Hz, 2H), 2.45 (d, J = 2.4 Hz, 2H), 2.03 (s, 1H), 1.60 (s, 4H), 1.24 (s, 3H). 
13
C NMR (CDCl3, 101 MHz) δ 169.99, 168.80, 141.13, 137.36, 122.29, 118.99, 82.58, 77.16, 
76.53, 75.48, 75.11, 65.87, 56.76, 53.88, 52.93, 49.51, 47.79, 45.89, 36.24, 36.00, 17.61, 17.49. 
HRMS:  
[M+NH4]+ calculated for C22H28O7N: 418.1866 m/z; found 418.1808 m/z.  
[M+Na]+ calculated for C22H24O7Na: 423.1866 m/z; found 423.1845 m/z.   
[2M+Na]+ calculated for C44H48O14Na 823.2942 m/z; found 823.2908 m/z. 
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The procedure was adapted from biotin labeling of sterols
103
.  To a solution of propargyl repin 
(7mg, 1 eq) and biotin-PEG3-azide (8mg, 1.03 eq) in tetrahydrofuran (0.08 mL), t-butanol  (0.04 
mL) and water (0.02) was added a solution of copper(II) sulfate pentahydrate (.62mg, 0.22 eq in 
0.01 mL of water) and a solution of sodium ascorbate (1.5 mg, 0.44 eq in water (0.01 mL), 
respectively.  After stirring at 30
o
C for 36 h, the solvent was removed by evaporation and residue 
was extracted by ethyl acetate (2 x 5 mL).  Combined organic extracts were washed with water 
(3 x 5 mL), saturated aqueous NaCl (2 × 10 mL) and dried over anhydrous Na2SO4. The residue 
was then purified by preparative thin layer chromatography (15:8:4:1 ethyl 
acetate/chloroform/methanol/water).  This gave impure biotin labeled repin (4mg, 27%) as a 
white solid. 
HRMS:  [M+Na]+ calculated for C40H56N6NaO12S: 867.3575 m/z; found 867.3570 m/z.   
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APPENDIX I: REPIN BIOLOGICAL ASSAY RESULTS   
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  General Description of Repin Kinase Assay 
The assay used for repin (KINOMEscan
TM
 by DiscoverX), does not require ATP and allow 
reporting of thermodynamic interaction affinities instead of IC50 values which are often used 
and can be influenced by ATP concentration.The kinase may bind the ligand in either an 
orthosteric (in active site) or allosteric fashion (indirectly).   Both cases may inhibit enzymatic 
activity and potentially downstream signaling associated with the kinase.  In in the figure 
below(A), target kinases (squiggly, blue) are allowed to interact with immobilized ligand 
(orange) in the absence of test compound.  Test  compounds (gray) either interfere with kinase 
binding to immobilized ligands (B) or do not interfere (C).  The compounds and unbound kinase 
is washed away and the amount captured is compared to control samples and quantitatively 
measured using qPCR of the associated DNA label for each target protein
94
.    
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Experimental details of Kinome Scan Assay 
For the majority of the assays, kinase-tagged T7 phage strains were grown in 24-well blocks in 
an E. coli host (derived from the BL21 strain). After being grown to log-phase, the E.coli was 
infected with T7 phage (multiplicity of infection = 0.4) and incubated with shaking at 32°C until 
lysis (90-150 minutes). The lysates were and filtered (0.2µm) to remove cell debris. The 
remaining kinases were produced in HEK-293 cells and subsequently tagged with DNA for 
qPCR detection.  
Affinity resins for kinase assays were generated by treating streptavidin-coated magnetic beads 
with biotinylated small molecule ligands for 30 minutes at room temperature. 
These beads were then blocked with excess biotin and washed with blocking buffer (SeaBlock 
by Pierce Biotechnology), 1 % BSA, 0.05 % Tween 20, 1 mM DTT) to wash unbound ligand 
and to reduce non-specific phage binding. Binding reactions were assembled by combining 
kinases, liganded affinity beads, and test compounds in 1x binding buffer (20 % SeaBlock, 0.17x 
PBS, 0.05 % Tween 20, 6 mM DTT). Test compounds were prepared in DMSO as 40x stocks 
and directly diluted into the assay.  All reactions were performed in 384-well plates in a final 
volume of 0.02 ml. The assay plates were incubated at room temperature for 1 hour with 
shaking.  At this point, the affinity beads were washed buffer consisting of 1x PBS, 0.05 % 
Tween 20. The beads were then re-suspended in elution buffer (1x PBS, 0.05 % Tween 20, 0.5 
µM non-biotinylated affinity ligand) and incubated at room temperature with shaking for 30 
minutes. The kinase concentration in the eluates was measured by qPCR
94
. 
The compounds were screened at 1 micromolar concentration.  The results were reported as 
“percent of control” (% Ctrl) .  To calculate percent of control, the following formula was used: 
96 
 
 
Where: 
test compound = compound submitted by our lab (repin) 
negative control = DMSO (100% control)  
positive control = control compound (0% control) 
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Results of KinomeScan assay (DiscoverX - Eurofins) 
Table 3 
DiscoveRx Gene Symbol 
Entrez Gene 
Symbol % Control 
ABL1-nonphosphorylated ABL1 71 
ABL1-phosphorylated ABL1 81 
AURKA AURKA 100 
CDK5 CDK5 99 
CHEK1 CHEK1 98 
CSNK2A2 CSNK2A2 100 
DYRK2 DYRK2 83 
ERK1 MAPK3 100 
ERK2 MAPK1 100 
GRK1 GRK1 91 
GRK2 ADRBK1 94 
GRK3 ADRBK2 57 
GRK4 GRK4 83 
JNK1 MAPK8 100 
JNK2 MAPK9 93 
JNK3 MAPK10 100 
LKB1 STK11 66 
LRRK2 LRRK2 91 
LRRK2(G2019S) LRRK2 100 
MEK1 MAP2K1 98 
MEK4 MAP2K4 100 
MKK7 MAP2K7 100 
MLK2 MAP3K10 100 
MLK3 MAP3K11 92 
p38-alpha MAPK14 100 
p38-beta MAPK11 100 
p38-delta MAPK13 100 
p38-gamma MAPK12 100 
PKN1 PKN1 100 
PRKCD PRKCD 89 
PRKCE PRKCE 98 
PRKCH PRKCH 100 
PRKCI PRKCI 87 
PRKCQ PRKCQ 77 
PRKD1 PRKD1 100 
PRKD3 PRKD3 97 
PYK2 PTK2B 100 
RIPK1 RIPK1 100 
RIPK2 RIPK2 96 
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EnPlex Assay Results and Description (Bachovchin Lab) 
 
“Purified enzymes are coupled to Luminex microspheres, with a different bead color for each 
enzyme. Multiplexed bead complexes are incubated with a compound before being treated with a 
biotinylated activity-based probe and a streptavidin R–phycoerythrin conjugate (SASAPE). The 
mixtures are scanned on a Luminex flow cytometer, where one laser detects the bead color 
(enzyme identity) and a second laser detects the R-phycoerythrin signal (enzyme activity).  
Changes in absorbance are due to interruption of SAPE interaction by an inhibitor
93.”  
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Figure 25: EnPlex Assay Results:  Repin showed no activity pattern across any protease.  
Positive DPP4 hit (ValboroPro, left lane) compared to repin (listed as MJC-1-21, right lane). 
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